Chris Moore discusses key considerations for US biotechs setting up gene therapy studies in Europe

In the viewpoint article: ‘Key considerations for US biotechs setting up gene therapy studies in the UK and Europe’, Chris highlights some of the important things organisations must consider before initiating their study.